Back to Journals » Clinical Ophthalmology » Volume 4

The controversy over the association between statins use and progression of age-related macular degeneration: a mini review

Authors Peponis V, Chalkiadakis S, Bonovas S, Sitaras NM

Published 29 July 2010 Volume 2010:4 Pages 865—869


Review by Single anonymous peer review

Peer reviewer comments 3

Vasileios Peponis1, Spyridon E Chalkiadakis1, Stefanos Bonovas2,3, Nikolaos M Sitaras2

1Athens Eye Hospital, 2nd Eye Clinic, Athens, Greece; 2Department of Pharmacology, School of Medicine, University of Athens, Greece; 3Center for Diseases Control and Prevention, Athens, Greece

Objective: Age-related macular degeneration (AMD) is the leading cause of blindness in ¬western societies. Statins comprise a class of pharmacological agents that reduce plasma cholesterol levels, and have been shown to prevent progression of atherosclerosis and reduce cardiovascular mortality. The relationship between these medications and AMD has been evaluated in several recent studies. Herein, we examine the current evidence for an association between statin use and risk of AMD.
Methods: Literature database search (Medline, Scopus, and Science Citation Index Expanded) for articles published up to March 2010, using particular search terms.
Results: From the current evidence available, it is not safe to conclude upon the assumption of a protective effect of statins against age-related maculopathy and AMD.
Conclusion: There is a need for large scale prospective studies with a long follow-up period and accurate assessment of AMD to further explore this matter.

Keywords: age-related macular degeneration (AMD), blindness, statin use, controversy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.